Cell, gene-modified cell and gene therapies hold the promise to offer new hope and novel therapeutic avenues for individuals facing serious illnesses and medical conditions. But bringing these therapies successfully through the clinical trial process introduces a level of supply chain risk, complexity and specialized requirements which are not yet fully understood. This webinar focuses on taking a closer look at unique clinical supply challenges and unique needs associated with cell and gene therapies.

Featured Speaker

Martin Lamb

Global Director of Client Services, Clinical Supply Services

Martin Lamb is Global Director of Catalent Pharma Solutions’ CSS business unit. In this role, he oversees our Client Services teams at our US, EU and APAC clinical supplies sites, in addition to providing input into strategic initiatives within the CSS business unit. Previous roles at Catalent include European Director of Business Development where he focused on developing Catalent’s clinical supplies business with European pharmaceutical and biotech companies. Prior to joining Catalent, Martin was Global VP of Business Development for Almac Clinical Services. Most recently, Martin was Chief Business Officer for TrakCel, a company engaged in the development of bespoke software solutions for the orchestration of activities across multiple stakeholders in Cell and Gene Therapy supply chains. Martin holds a BSc in Pharmacology from the University of Leeds, UK and postgraduate Marketing qualifications from Queens University, Belfast and the Chartered Institute of Marketing.


Register now for this webinar